Renal disease News and Research

RSS

Tengion 2010 adjusted net loss decreases to $25.8 million

Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.

25 Mar 2011

ACE, ARB combination therapy may increase risk of kidney failure, death

Elderly patients prescribed combination angiotensin converting enzyme inhibitors and angiotensin receptor blockers had a higher risk of kidney failure and death, according to a study published in CMAJ.

22 Mar 2011

Hopkins experts: Taking potassium iodide could be harmful

The Johns Hopkins Office of Critical Event Preparedness and Response (CEPAR) is advising that people in the United States should not take potassium iodide as a preventive medication for possible radiation fallout from Japan's evolving nuclear plant crisis.

17 Mar 2011

Experts advise against taking unnecessary potassium iodide

There is a mad rush to the stores to pick up potassium iodide supplements to guard against radiation exposure wafting over to the U.S. from Japan, an unlikely event according to experts. This is despite health officials’ warnings that these supplements are pointless and could cause adverse side effects.

16 Mar 2011

New study on how epoxyeicosatrienoic acids protect kidneys

Researchers at Georgia Health Sciences University are studying whether inhibiting an enzyme that reduces levels of a protective metabolite could halt the progression of diabetic nephropathy, or kidney disease resulting from diabetes.

16 Mar 2011

KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease (ESRD).

14 Mar 2011

FMCNA encourages high blood pressure, diabetes people to learn about risk of CKD

Diabetes and high blood pressure are the two leading causes of chronic kidney disease, a health problem that is growing at an alarming rate in the United States. There are 26 million Americans who have CKD, and millions more are at increased risk and may not even know it.

11 Mar 2011

Depression is linked with increased risk of developing kidney failure

Depression is associated with an increased risk of developing kidney failure in the future, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

10 Mar 2011

CUBN gene mutation linked with albuminuria in individuals with or without diabetes

A team of researchers from the United States and Europe has identified a single genetic mutation in the CUBN gene that is associated with albuminuria both with and without diabetes. Albuminuria is a condition caused by the leaking of the protein albumin into the urine, which is an indication of kidney disease.

9 Mar 2011

DaVita earns recognition in Fortune's Most Admired Companies list

DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease and chronic kidney disease, has been honored as one of the 2011 Fortune World's Most Admired Companies, and ranked second in the Health Care: Medical Facilities industry.

5 Mar 2011

European Commission approves BMY's ONGLYZA to treat type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved a label update for ONGLYZA in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment. The approved dosage for the patient group is a new once-daily 2.5 mg dose.

4 Mar 2011

Racial and ethnic groups less likely to receive kidney transplants than others

Not all racial and ethnic groups have equal access to kidney transplantation, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The results indicate that the reasons for these disparities are varied and that more focused efforts are needed to address them.

3 Mar 2011

Rockwell Medical fourth quarter net loss increases to $1.7 million

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported today fourth quarter and full-year 2010 results.

3 Mar 2011

Patients with end-stage renal disease who opt for PD experience no greater risk of catheter infection

Patients with end-stage renal disease who opt for peritoneal dialysis experience no greater risk of catheter infection than those who undergo hemodialysis, a retrospective study at UT Southwestern Medical Center has found.

3 Mar 2011

Intercell reports EUR 255.2m net loss for full year 2010

Today Intercell AG announced its financial results for Q4 and the preliminary results for the full financial year 2010 and presented an update on the Company's development programs.

1 Mar 2011

AMAG fourth quarter total revenues increase to $17.2 million

AMAG Pharmaceuticals, Inc. a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2010.

25 Feb 2011

Study: More effective therapies needed for diabetes patients with ESRD

Despite significant advances in kidney care over the past 20 years, efforts to improve therapy for type 1 diabetes patients with kidney dysfunction remain unsuccessful, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The results suggest that more effective therapies are needed for these patients.

24 Feb 2011

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Isis Pharmaceuticals, Inc. announced today the results from a Phase 1 clinical trial in which ISIS-CRPRx produced statistically significant reductions in C-reactive protein in the cohort of subjects in the study with elevated CRP.

24 Feb 2011

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

24 Feb 2011

GORE PROPATEN Vascular Graft for hemodialysis access receives CE Mark approval

W. L. Gore & Associates announced the GORE PROPATEN Vascular Graft for hemodialysis access has received CE Mark. Arteriovenous Grafts are used to create a conduit for repeated blood access during hemodialysis, allowing blood to be withdrawn from the body and cleansed when a patient has End Stage Renal Disease, commonly referred to as kidney failure.

22 Feb 2011